Leukocytoclastic vasculitis
ICD-10 L95.9 · ICD-11 4A44.B0

Treatment of Leukocytoclastic Vasculitis with Systemic Organ Involvement

Clinical Scenario

This protocol addresses leukocytoclastic vasculitis (LCV) when it presents with systemic organ involvement — a setting where an underlying systemic vasculitis, rather than a self-limited cutaneous cause, is responsible for the disease.

Associated Conditions

This scenario encompasses LCV occurring in the context of:

ANCA-associated vasculitis Cryoglobulinemic vasculitis IgA vasculitis Hypocomplementemic urticarial vasculitis Connective tissue disease

When a systemic vasculitis underlies LCV, the specific associated disease and the degree of organ involvement both shape the treatment required.

Treatment Approach

Management in this setting involves systemic corticosteroid therapy. The intensity of treatment is guided by the severity of organ involvement and the nature of the underlying condition. The full regimen — including agent selection, dose escalation criteria, and any additional therapies — is specified in the complete protocol.

Treatment Goal
Disease remission
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/rheumatology/keac115 Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease. Corticosteroids use is widely accepted but the dosage depends on severity; severe form may require initial doses of 0.5–1 mg/kg/day of prednisone equivalents. In general, the treatment depends on the diagnosis and aims to induce and maintain disease remission. View source ↗